Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
UKPDS
About the Trial
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive treatment with sulfonylureas or insulin lowered HbA1c to 7.0 percent and reduced microvascular endpoints by 25 percent. Metformin in overweight patients reduced myocardial infarction and death. The blood pressure arm showed tight control at 144 over 82 reduced strokes, heart failure, and diabetes related death. Unlike type 1 diabetes, glucose had modest macrovascular effects. The 10 year post trial follow up showed legacy effects of glucose control persisting for a decade after the trial ended, while the blood pressure benefits faded once control was relaxed.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...
EMPA-REG OUTCOME
EMPA-REG OUTCOME randomized 7,020 type 2 diabetes patients with cardiovascular disease to the SGLT2 inhibitor empagliflozin or pla...